MX2018007449A - Compuestos novedosos. - Google Patents
Compuestos novedosos.Info
- Publication number
- MX2018007449A MX2018007449A MX2018007449A MX2018007449A MX2018007449A MX 2018007449 A MX2018007449 A MX 2018007449A MX 2018007449 A MX2018007449 A MX 2018007449A MX 2018007449 A MX2018007449 A MX 2018007449A MX 2018007449 A MX2018007449 A MX 2018007449A
- Authority
- MX
- Mexico
- Prior art keywords
- relates
- compounds
- novel compounds
- inhibitors
- ubiquitin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
La presente invención se refiere a compuestos novedosos y a métodos para la fabricación de inhibidores de enzimas desubiquitinantes (DUB); en particular, la invención se refiere a la inhibición de la hidrolasa 30 de la C-terminal de la ubiquitina o Peptidasa 30 Específica de Ubiquitina (USP30); la invención se refiere además al uso de los inhibidores de DUB en el tratamiento de condiciones que involucran disfunción mitocondrial y cáncer; los compuestos de la invención incluyen compuestos que tienen la Fórmula (I): (ver Fórmula) o una sal farmacéuticamente aceptable de los mismos, en donde R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L y A son como se definieron en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1522267.2A GB201522267D0 (en) | 2015-12-17 | 2015-12-17 | Novel compounds |
PCT/GB2016/053971 WO2017103614A1 (en) | 2015-12-17 | 2016-12-16 | Novel Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018007449A true MX2018007449A (es) | 2018-11-09 |
Family
ID=55311125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018007449A MX2018007449A (es) | 2015-12-17 | 2016-12-16 | Compuestos novedosos. |
Country Status (19)
Country | Link |
---|---|
US (2) | US11130748B2 (es) |
EP (2) | EP3390391B1 (es) |
JP (1) | JP6898327B2 (es) |
CN (1) | CN108368089B (es) |
AU (1) | AU2016373533B2 (es) |
BR (1) | BR112018007208B1 (es) |
CA (1) | CA3008747C (es) |
CO (1) | CO2018006299A2 (es) |
ES (1) | ES2929376T3 (es) |
GB (1) | GB201522267D0 (es) |
HK (1) | HK1256059A1 (es) |
IL (1) | IL258444B (es) |
MA (1) | MA44050A (es) |
MX (1) | MX2018007449A (es) |
MY (1) | MY196729A (es) |
RU (1) | RU2734256C2 (es) |
SG (1) | SG11201804934PA (es) |
WO (1) | WO2017103614A1 (es) |
ZA (1) | ZA201804739B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3943490A1 (en) | 2015-03-30 | 2022-01-26 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
GB201522267D0 (en) * | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
GB201602854D0 (en) * | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
WO2017163078A1 (en) | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
EP3519385B1 (en) | 2016-09-27 | 2020-11-18 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of usp30 |
GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
GB201616627D0 (en) * | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
US11059809B2 (en) | 2017-06-20 | 2021-07-13 | Mission Therapeutics Limited | Substituted cyanopyrrolidines with activity as DUB inhibitors |
US11247987B2 (en) * | 2017-10-06 | 2022-02-15 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
GB2571731A (en) * | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
WO2019180686A1 (en) * | 2018-03-23 | 2019-09-26 | Cmg Pharmaceutical Co., Ltd. | Ido-tdo dual inhibitor and related methods of use |
EP3793997B1 (en) * | 2018-05-17 | 2024-03-13 | Forma Therapeutics, Inc. | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
US20210179628A1 (en) * | 2018-08-09 | 2021-06-17 | Valo Early Discovery, Inc. | Inhibiting deubiquitinase usp25 and usp28 |
US11572374B2 (en) | 2018-08-14 | 2023-02-07 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
PL3860989T3 (pl) * | 2018-10-05 | 2023-07-10 | Forma Therapeutics, Inc. | Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30) |
GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
WO2021200934A1 (ja) * | 2020-03-30 | 2021-10-07 | 国立大学法人 長崎大学 | 抗マラリア薬 |
WO2021204856A1 (en) | 2020-04-08 | 2021-10-14 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
IL298526A (en) | 2020-05-28 | 2023-01-01 | Mission Therapeutics Ltd | Development of n-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide and corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction |
KR20230019198A (ko) | 2020-06-04 | 2023-02-07 | 미션 테라퓨틱스 엘티디 | Usp30 억제제로서의 활성을 갖는 n-시아노피롤리딘 |
KR20230022215A (ko) | 2020-06-08 | 2023-02-14 | 미션 테라퓨틱스 엘티디 | 미토콘드리아 기능장애, 암 및 섬유증의 치료에 사용하기 위한 USP30 억제제로서 1-(5-(2-시아노피리딘-4-일)옥사졸-2-카보닐)-4-메틸헥사하이드로피롤로[3,4-b]피롤-5(1H)-카보니트릴 |
GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1272467A4 (en) * | 2000-04-06 | 2003-05-07 | Merck Frosst Canada Inc | Cathepsin cysteine PROTEASE INHIBITORS |
RU2515968C2 (ru) * | 2007-04-11 | 2014-05-20 | Киссеи Фармасьютикал Ко., Лтд. | 5-членное гетероциклическое соединение и его применение для лекарственных целей |
EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
WO2015179190A1 (en) * | 2014-05-19 | 2015-11-26 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof |
GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
EP3943490A1 (en) | 2015-03-30 | 2022-01-26 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
GB201522267D0 (en) * | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
WO2017163078A1 (en) | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
EP3519385B1 (en) | 2016-09-27 | 2020-11-18 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of usp30 |
GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
US11059809B2 (en) * | 2017-06-20 | 2021-07-13 | Mission Therapeutics Limited | Substituted cyanopyrrolidines with activity as DUB inhibitors |
-
2015
- 2015-12-17 GB GBGB1522267.2A patent/GB201522267D0/en not_active Ceased
-
2016
- 2016-12-16 CN CN201680073270.2A patent/CN108368089B/zh active Active
- 2016-12-16 RU RU2018123779A patent/RU2734256C2/ru active
- 2016-12-16 BR BR112018007208-7A patent/BR112018007208B1/pt active IP Right Grant
- 2016-12-16 US US15/781,615 patent/US11130748B2/en active Active
- 2016-12-16 MY MYPI2018000546A patent/MY196729A/en unknown
- 2016-12-16 MX MX2018007449A patent/MX2018007449A/es unknown
- 2016-12-16 WO PCT/GB2016/053971 patent/WO2017103614A1/en active Application Filing
- 2016-12-16 JP JP2018531219A patent/JP6898327B2/ja active Active
- 2016-12-16 SG SG11201804934PA patent/SG11201804934PA/en unknown
- 2016-12-16 EP EP16816365.7A patent/EP3390391B1/en active Active
- 2016-12-16 EP EP22195076.9A patent/EP4122929A1/en active Pending
- 2016-12-16 ES ES16816365T patent/ES2929376T3/es active Active
- 2016-12-16 AU AU2016373533A patent/AU2016373533B2/en active Active
- 2016-12-16 CA CA3008747A patent/CA3008747C/en active Active
- 2016-12-16 MA MA044050A patent/MA44050A/fr unknown
-
2018
- 2018-03-28 IL IL258444A patent/IL258444B/en active IP Right Grant
- 2018-06-18 CO CONC2018/0006299A patent/CO2018006299A2/es unknown
- 2018-07-16 ZA ZA2018/04739A patent/ZA201804739B/en unknown
- 2018-11-26 HK HK18115116.7A patent/HK1256059A1/zh unknown
-
2021
- 2021-08-16 US US17/402,802 patent/US11958833B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2016373533B2 (en) | 2020-06-11 |
CA3008747A1 (en) | 2017-06-22 |
MA44050A (fr) | 2018-10-24 |
BR112018007208A2 (pt) | 2018-10-16 |
CN108368089A (zh) | 2018-08-03 |
JP6898327B2 (ja) | 2021-07-07 |
US20210380562A1 (en) | 2021-12-09 |
WO2017103614A1 (en) | 2017-06-22 |
CN108368089B (zh) | 2021-07-06 |
EP3390391A1 (en) | 2018-10-24 |
SG11201804934PA (en) | 2018-07-30 |
US20200172516A1 (en) | 2020-06-04 |
EP3390391B1 (en) | 2022-09-14 |
BR112018007208B1 (pt) | 2024-01-23 |
EP4122929A1 (en) | 2023-01-25 |
KR20180095625A (ko) | 2018-08-27 |
GB201522267D0 (en) | 2016-02-03 |
RU2018123779A3 (es) | 2020-02-18 |
US11130748B2 (en) | 2021-09-28 |
HK1256059A1 (zh) | 2019-09-13 |
US11958833B2 (en) | 2024-04-16 |
AU2016373533A1 (en) | 2018-07-05 |
RU2734256C2 (ru) | 2020-10-13 |
NZ741411A (en) | 2022-03-25 |
RU2018123779A (ru) | 2020-01-17 |
JP2019504009A (ja) | 2019-02-14 |
CO2018006299A2 (es) | 2018-07-10 |
IL258444B (en) | 2020-08-31 |
IL258444A (en) | 2018-05-31 |
CA3008747C (en) | 2023-06-13 |
MY196729A (en) | 2023-05-03 |
ZA201804739B (en) | 2020-01-29 |
ES2929376T3 (es) | 2022-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY196729A (en) | Novel compounds | |
MY188957A (en) | 1-cyano-pyrrolidine compounds as usp30 inhibitors | |
MX2017003358A (es) | Compuestos novedosos. | |
WO2017109488A8 (en) | Cyanopyrrolidine derivatives as inhibitors for dubs | |
MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
PH12015502018A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
PH12016501338A1 (en) | Indazole compounds as irak4 inhibitors | |
MX2015012822A (es) | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. | |
SG10201811204RA (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
MD20150085A2 (ro) | Inhibitori ai histon-demetilazelor | |
WO2017100362A3 (en) | Inhibitors of ezh2 and methods of use thereof | |
MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
TW201625535A (en) | Inhibitors of histone demethylases | |
NZ738389A (en) | Inhibitor of igfbp3/tmem219 axis and diabetes | |
MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
WO2019118727A3 (en) | Rescue of the pathology of lrrk2 on lysosmes with snx25 or snx27 | |
ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
MX2022006750A (es) | Inhibidores de masp-2 y metodos de uso. | |
MX2018006374A (es) | Compuestos de bis-piridazina y su uso en el tratamiento del cancer. | |
AU2018258588A8 (en) | Inhibitors of TRIM33 and methods of use | |
MX2021011699A (es) | Derivados de quinolina y su uso para el tratamiento del cancer. | |
WO2018067638A3 (en) | High mobility group b1 protein inhibitors | |
MX2019014773A (es) | Inhibidores de ccl2. |